Skip to main content
Premium Trial:

Request an Annual Quote

Schering Expands Target Validation Collaboration with Atugen to Include RNAi

NEW YORK, June 17 - Schering has extended a collaboration with Atugen of Berlin to validate drug targets associated with cancer using Atugen's KnockDown technology.

 

The two companies have been collaborating for six years so far. The new agreement adds two more years to the partnership, and has been expanded to include Atugen's RNA interference technology. Atugen will develop its GeneBloc antisense molecules and/or siRNA molecules that are designed to inhibit expression of drug target candidates selected by Schering. Atugen will analyze the effects of the knockdown to validate gene function and disease association.

 

Under the terms of the new agreement, Atugen will receive annual licensing fees, research funding, and milestone payments.

 

Atugen will be working with Schering's research scientists in Germany and its Berlex Biosciences subsidiary in California.

The Scan

Team Tracks Down Potential Blood Plasma Markers Linked to Heart Failure in Atrial Fibrillation Patients

Researchers in BMC Genomics found 10 differentially expressed proteins or metabolites that marked atrial fibrillation with heart failure cases.

Study Points to Synonymous Mutation Effects on E. Coli Enzyme Activity

Researchers in Nature Chemistry saw signs of enzyme activity shifts in the presence of synonymous mutations in a multiscale modeling analysis of three Escherichia coli genes.

Team Outlines Paternal Sample-Free Single-Gene Approach for Non-Invasive Prenatal Screening

With data for nearly 9,200 pregnant individuals, researchers in Genetics in Medicine demonstrate the feasibility of their carrier screening and reflex single-gene non-invasive prenatal screening approach.

Germline-Targeting HIV Vaccine Shows Promise in Phase I Trial

A National Institutes of Health-led team reports in Science that a broadly neutralizing antibody HIV vaccine induced bnAb precursors in 97 percent of those given the vaccine.